CELL INTELLIGENCE · 肿瘤细胞治疗研究

靶向 B 细胞成熟抗原的 CAR-T 细胞作为抗 G 蛋白偶联受体 C 类 5 组成员 D CAR-T 细胞治疗后进展性多发性骨髓瘤的挽救治疗

B-cell maturation antigen-targeted CAR T cell as a salvage therapy for progressive multiple myeloma after anti-G proteincoupled receptor, class C grou

下一代基于抗体的癌症治疗：抗体-药物偶联物和双特异性抗体在血液系统恶性肿瘤和实体瘤中的应用

Next-generation antibody-based therapeutics in cancer: antibody-drug conjugates bispecific antibodies across hematologic malignancies and solid tumors

超越缓解：多发性骨髓瘤 CAR-T 治疗后的风险适应维持治疗与机制指导的挽救治疗

Beyond Remission: Risk-Adapted Maintenance and Mechanism-Guided Salvage After CAR T-Cell Therapy for Multiple Myeloma.

对于持续性 MRD 阴性、无髓外疾病且免疫功能正在恢复的许多患者，结构化观察是合适的。持续性或升高的 MRD、残留病灶、侵袭性疾病生物学特征或不利的 CAR-T 细胞动力学，应促使尽早转介临床试验，而非自动进行慢性治疗。挽救治疗可能涉及 BCMA 再靶向、转换为 GPRC5D 或 FcRH5、常规减瘤、放疗、抗体-药物偶联物、双特异性抗体或第二种细胞平台。未来试验应评估无进展生存期，同时评估无感染生存期、无治疗间期、免疫恢复、生活质量以

抗 BCMA/GPRC5D CAR-T 细胞用于伴骨外髓外病变的复发/难治性多发性骨髓瘤患者

Anti-BCMA/GPRC5D CAR T cells in patients with relapsed or refractory multiple myeloma who have extraosseous extramedullary disease.

BCMA 靶向治疗后的复发/难治性多发性骨髓瘤的后续 CAR-T 与工程化抗体：系统综述与荟萃分析

Subsequent CAR-T and engineered antibody for relapsed/refractory multiple myeloma following BCMA-targeted treatment: a systematic review and meta-anal

超越双靶向：重新定义真正髓外骨髓瘤的治疗格局？——一项批判性评价

Beyond dual targeting: redefining the treatment horizon for true extramedullary myeloma? - a critical appraisal.

全人源抗 GPRC5D CAR-T 细胞疗法 RD118 在复发/难治性多发性骨髓瘤中诱导持久缓解

The fully human anti-GPRC5D CAR T-cell therapy RD118 induces durable remissions in relapsed/refractory multiple myeloma.

靶向 GPRC5D 的 CAR-T 细胞治疗复发/难治性多发性骨髓瘤：病例报告与文献综述

Targeting GPRC5D With CAR-T Cells in Relapse/Refractory Multiple Myeloma: Case Report and Literature Review.

靶向 GPRC5D 的 CAR-T 细胞疗法（CT071）治疗复发/难治性多发性骨髓瘤患者：一项首次人体、单中心、单臂、I 期试验

GPRC5D-targeted CAR T-cell therapy (CT071) in patients with relapsed or refractory multiple myeloma: a first-in-human, single-centre, single-arm, phas

CT071 在复发/难治性多发性骨髓瘤患者中显示出令人鼓舞的安全性特征和引人注目的活性。

G 蛋白偶联受体 C 类 5 组成员 D 靶向免疫治疗在多发性骨髓瘤中的新兴作用：进展、耐药与联合策略

Emerging role of G protein-coupled receptor class C group 5 member D-directed immunotherapy in multiple myeloma: Advances, resistance and combination